Primary Angioplasty: Preprocedural Pharmacological Therapy

Overview

Journal Neth Heart J

Specialty Cardiology & Vascular Diseases

Date 2015 Feb 20

PMID 25696594

Citations 1

Authors

N Ernst

M-J de Boer

F Zijlstra

H Suryapranata

J-H E Dambrink

J C A Hoorntje

A W J van t Hof

Affiliations

Soon will be listed here.

Abstract

Primary coronary angioplasty has been shown to be an effective reperfusion therapy for patients with acute myocardial infarction, not only for those who present to PTCA centres but also for patients who present to hospitals without angioplasty facilities. With the increasing use of primary angioplasty more patients will be transferred to a (tertiary) PTCA centre. An increase in treatment delay is associated with a worse clinical outcome. The importance of an open infarct-related vessel at acute angiography is becoming clear. Pharmacological pretreatment of patients during transportation to a PTCA centre with the aim to open the infarct-related vessel in advance might be beneficial. Glycoprotein IIb/IIIa receptor blockers seem to be the agents of choice for facilitated PTCA. The safety and (cost) effectiveness of this pretreatment of patients transported to undergo primary angioplasty remain to be evaluated.

Citing Articles

Prehospital diagnosis in STEMI patients treated by primary PCI: the key to rapid reperfusion.

Vermeulen R, Jaarsma T, Hanenburg F, Nannenberg J, Jessurun G, Zijlstra F Neth Heart J. 2008; 16(1):5-9.

PMID: 18317537 PMC: 2246312. DOI: 10.1007/BF03086109.

References

Dalby M, Bouzamondo A, Lechat P, Montalescot G . Transfer for primary angioplasty versus immediate thrombolysis in acute myocardial infarction: a meta-analysis. Circulation. 2003; 108(15):1809-14. DOI: 10.1161/01.CIR.0000091088.63921.8C. View

de Lemos J, Antman E, Gibson C, McCabe C, Giugliano R, Murphy S . Abciximab improves both epicardial flow and myocardial reperfusion in ST-elevation myocardial infarction. Observations from the TIMI 14 trial. Circulation. 2000; 101(3):239-43. DOI: 10.1161/01.cir.101.3.239. View

Zijlstra F, van t Hof A, Liem A, Hoorntje J, Suryapranata H, de Boer M . Transferring patients for primary angioplasty: a retrospective analysis of 104 selected high risk patients with acute myocardial infarction. Heart. 1997; 78(4):333-6. PMC: 1892264. DOI: 10.1136/hrt.78.4.333. View

Topol E . Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial. Lancet. 2001; 357(9272):1905-14. DOI: 10.1016/s0140-6736(00)05059-5. View

Montalescot G, Borentain M, Payot L, Collet J, Thomas D . Early vs late administration of glycoprotein IIb/IIIa inhibitors in primary percutaneous coronary intervention of acute ST-segment elevation myocardial infarction: a meta-analysis. JAMA. 2004; 292(3):362-6. DOI: 10.1001/jama.292.3.362. View

Dudek D, Zmudka K, Kaluza G, Kuta M, Pieniazek P, Przewlocki T . Facilitated percutaneous coronary intervention in patients with acute myocardial infarction transferred from remote hospitals. Am J Cardiol. 2003; 91(2):227-9. DOI: 10.1016/s0002-9149(02)03112-0. View

. Trial of abciximab with and without low-dose reteplase for acute myocardial infarction. Strategies for Patency Enhancement in the Emergency Department (SPEED) Group. Circulation. 2000; 101(24):2788-94. DOI: 10.1161/01.cir.101.24.2788. View

Liem A, van t Hof A, Hoorntje J, de Boer M, Suryapranata H, Zijlstra F . Influence of treatment delay on infarct size and clinical outcome in patients with acute myocardial infarction treated with primary angioplasty. J Am Coll Cardiol. 1998; 32(3):629-33. DOI: 10.1016/s0735-1097(98)00280-0. View

. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction. Lancet. 2001; 358(9282):605-13. DOI: 10.1016/S0140-6736(01)05775-0. View

10.

Grines C, Browne K, Marco J, Rothbaum D, Stone G, Okeefe J . A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction. The Primary Angioplasty in Myocardial Infarction Study Group. N Engl J Med. 1993; 328(10):673-9. DOI: 10.1056/NEJM199303113281001. View

11.

Brener S, Barr L, Burchenal J, Katz S, GEORGE B, Jones A . Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators. Circulation. 1998; 98(8):734-41. DOI: 10.1161/01.cir.98.8.734. View

12.

Antman E, Giugliano R, Gibson C, McCabe C, Coussement P, Kleiman N . Abciximab facilitates the rate and extent of thrombolysis: results of the thrombolysis in myocardial infarction (TIMI) 14 trial. The TIMI 14 Investigators. Circulation. 1999; 99(21):2720-32. DOI: 10.1161/01.cir.99.21.2720. View

13.

Liem A, Zijlstra F, Ottervanger J, Hoorntje J, Suryapranata H, de Boer M . High dose heparin as pretreatment for primary angioplasty in acute myocardial infarction: the Heparin in Early Patency (HEAP) randomized trial. J Am Coll Cardiol. 2000; 35(3):600-4. DOI: 10.1016/s0735-1097(99)00597-5. View

14.

Vermeer F, Oude Ophuis A, vd Berg E, Brunninkhuis L, Werter C, Boehmer A . Prospective randomised comparison between thrombolysis, rescue PTCA, and primary PTCA in patients with extensive myocardial infarction admitted to a hospital without PTCA facilities: a safety and feasibility study. Heart. 1999; 82(4):426-31. PMC: 1760265. DOI: 10.1136/hrt.82.4.426. View

15.

Stone G, Grines C, Cox D, Garcia E, Tcheng J, Griffin J . Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. N Engl J Med. 2002; 346(13):957-66. DOI: 10.1056/NEJMoa013404. View

16.

Ross A, Coyne K, Reiner J, GREENHOUSE S, Fink C, Frey A . A randomized trial comparing primary angioplasty with a strategy of short-acting thrombolysis and immediate planned rescue angioplasty in acute myocardial infarction: the PACT trial. PACT investigators. Plasminogen-activator Angioplasty.... J Am Coll Cardiol. 1999; 34(7):1954-62. DOI: 10.1016/s0735-1097(99)00444-1. View

17.

van den Merkhof L, Zijlstra F, Olsson H, Grip L, Veen G, Bar F . Abciximab in the treatment of acute myocardial infarction eligible for primary percutaneous transluminal coronary angioplasty. Results of the Glycoprotein Receptor Antagonist Patency Evaluation (GRAPE) pilot study. J Am Coll Cardiol. 1999; 33(6):1528-32. DOI: 10.1016/s0735-1097(99)00038-8. View

18.

De Luca G, Suryapranata H, Ottervanger J, Antman E . Time delay to treatment and mortality in primary angioplasty for acute myocardial infarction: every minute of delay counts. Circulation. 2004; 109(10):1223-5. DOI: 10.1161/01.CIR.0000121424.76486.20. View

19.

Zijlstra F, Hoorntje J, de Boer M, Reiffers S, Miedema K, Ottervanger J . Long-term benefit of primary angioplasty as compared with thrombolytic therapy for acute myocardial infarction. N Engl J Med. 1999; 341(19):1413-9. DOI: 10.1056/NEJM199911043411901. View

20.

Di Mario C, Bolognese L, Maillard L, Dudek D, Gambarati G, Manari A . Combined Abciximab REteplase Stent Study in acute myocardial infarction (CARESS in AMI). Am Heart J. 2004; 148(3):378-85. DOI: 10.1016/j.ahj.2004.03.038. View